API Corp

API Corporation is a leading Japanese Contract Development and Manufacturing Organization (CDMO) specializing in the production of active pharmaceutical ingredients (APIs) and intermediates. The company provides a comprehensive range of services including process development, scale-up, and commercial-scale GMP manufacturing for global pharmaceutical and biotech clients. Formerly a subsidiary of the Mitsubishi Chemical Group, API Corporation was acquired by the private equity firm J-STAR in 2023 and now operates as an independent entity. Its technical expertise is centered on complex organic synthesis, highly potent API (HPAPI) handling, and specialized peptide manufacturing. With multiple manufacturing facilities in Japan, the company is recognized for its high quality standards and advanced chemical technologies such as flow chemistry.